Sachi Bioworks, Inc.
Erie, CO
- UEI
- NTKPGKZLXPC1
- CAGE
- 8L8S8
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 3000 Airport Dr Unit 201, Erie, CO 80516, USA
- Website
- sachibio.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $3,850,000 |
| FY2025 | $1,673,923 |
| FY2024 | $1,535,844 |
| FY2023 | $995,236 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | National Aeronautics and Space Administration | $3,850,000 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase III - reversing immune dysregulation during spaceflight missions | Shared Services Center | $2,234,767 | |
| Definitive Contract 80NSSC23CA171 | Shared Services Center | $5,445,236 | |
| Purchase Order 80NSSC22PB175 | Shared Services Center | $166,498 | |
| Definitive Contract 80NSSC22CA116 | Shared Services Center | $1,974,984 | |
| Fast technology for reversing immune dysregulation during spaceflight missions | Shared Services Center | $131,498 |
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Colorado State University | R21AG085456 | $98,890 |
Similar vendors
About the company
Sachi Bioworks, Inc. is a self-certified small disadvantaged business located in Erie, Colorado, specializing in advanced biotechnology research and development with a focus on innovative drug discovery platforms. The company leverages its proprietary NanoligomerTM technology to develop novel therapeutic solutions across multiple scientific domains, including space-related medical research, immune system engineering, and targeted genetic interventions. Their core competency involves creating rapid, low-cost drug discovery processes that can be applied in complex environments such as microgravity conditions and specialized medical research contexts.
The company has secured multiple federal contract awards primarily from NASA under the Small Business Innovation Research (SBIR) program, concentrating on critical research related to immune system dysregulation during spaceflight missions. These contracts, totaling approximately $6,771,477, have progressively advanced through SBIR Phase I, II, and III stages, focusing on developing innovative drug discovery methodologies that can be conducted in space environments. Each contract was set aside for small businesses and involved developing rapid, low-cost technological approaches to address immune system challenges faced by astronauts during long-duration space travel, utilizing Sachi Bioworks' unique NanoligomerTM biotechnology platform.
Regarding federal grant awards, Sachi Bioworks has received notable funding from the Defense Health Agency and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A significant $1,979,313 grant from the Defense Health Agency, awarded in April 2025, supports the development of a brain-penetrant RNA therapeutic for amyotrophic lateral sclerosis (ALS) treatment. Additionally, a $131,498 NIDDK grant focused on developing nanoligomer-based therapeutics for inflammatory bowel disease, demonstrating the company's ability to apply its technological platform to diverse medical research challenges. These grants underscore Sachi Bioworks' commitment to advancing innovative therapeutic solutions across multiple complex medical domains, leveraging their proprietary NanoligomerTM technology to address significant health challenges.
Quick answers
Is Sachi Bioworks, Inc. registered in SAM.gov?
Yes. Sachi Bioworks, Inc.'s SAM.gov registration is active through July 10, 2027.
How much has Sachi Bioworks, Inc. received in federal contracts?
Federal contracts obligated $1,673,923 to Sachi Bioworks, Inc. in fiscal year 2025 and $8,055,003 in fiscal years 2023 through 2027.
How does Sachi Bioworks, Inc. rank among federal contractors?
Sachi Bioworks, Inc. ranked #58 in PSC AJ14 in FY2025.
What is Sachi Bioworks, Inc.'s most recent federal award?
Sachi Bioworks, Inc.'s most recent federal grant award is Novel brain-penetrant RNA therapeutic for treatment of amyotrophic lateral sclerosis (HT94252510181), from Defense Health Agency, on April 1, 2025.
On GovTribe
See Sachi Bioworks, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors